Tata Institute develops Rs 100 tablet which stops cancer recurrence
Advertisement
The tablet developed by Tata Memorial Centre (TMC) for preventing cancer recurrence is a significant breakthrough in cancer research and treatment. It offers a potentially affordable solution to a critical aspect of cancer management. However, its availability to the public hinges on the approval process from the Food Safety and Standards Authority of India (FSSAI).
According to the information provided, the tablet is currently awaiting approval from FSSAI. The scientists from Tata Institute of Fundamental Research (TIFR) have applied for approval, indicating a proactive step towards making the tablet accessible to the public. Once FSSAI grants approval, the tablet is expected to be available in the market by June-July.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.